Acceleron commences dalantercept phase 2 research in metastatic renal cell carcinoma Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a stage 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 pathway. Acceleron, its companions, and collaborators have now initiated seven phase 2 studies across three of Acceleron's applications – dalantercept , sotatercept , since November of 2012 and ACE-536.Nearly all patients were men, and the mean age was 51 years. A total of 89 percent of the study patients were white. Most patients had HCV RNA degrees of 800,000 IU or even more per milliliter at baseline. The majority of patients were infected with HCV genotype 1a. In total, 16 percent of the study population had cirrhosis. Furthermore, 57 percent of patients had been classified as having acquired a nonresponse to earlier HCV therapy, 36 percent as having got a relapse, and 7 percent as having acquired a breakthrough.001, P<0.001, and P=0.02, respectively) RNA Levels during and after the procedure Period, According to Treatment Group.). Responses by the end of the procedure period were higher in the telaprevir organizations than in the control group, seeing that were the responses at week 4 and week 12 .